ABVX

Abivax SA American Depositary Shares

$87.98

Current Price

All

AI analysis

Read what the AI thinks of Abivax SA American Depositary Shares in the app.

Analyses are generated by AI from public data and are not investment advice.

Get the app

Key figures

Dividend per share

—

Yield

—

EPS

-$5.82

P/E

—

Data as of Oct 8

Why it matters for the long term

Over 10-20 years, what drives a share up is the growth of its profits (EPS) + reinvested dividends. The P/E tells you whether you are paying a lot or a little for that growth. In short: rising EPS + reasonable P/E + growing dividend = good long-term candidate.

Upcoming events

Quarterly earnings

Dec 14

Posts

No posts about ABVX yet.

About Abivax SA American Depositary Shares

Abivax is a French biotechnology company that develops drugs for inflammatory diseases. Its lead candidate, obefazimod, is a pill being tested for ulcerative colitis and Crohn's disease, two long-term conditions that inflame the gut. The company has no approved product and no sales yet. It pays for research by raising money from investors.